Kurarinone Attenuates LPS-Induced Pneumonia by Inhibiting MAPK and NF-κB Signaling Pathways

Area of Science:

• Pharmacology
• Immunology
• Natural Products Chemistry

Background:

• Pneumonia remains a significant global health challenge, necessitating novel therapeutic strategies.
• Lipopolysaccharide (LPS) is a potent inducer of inflammation and a common model for studying pneumonia.
• Natural compounds offer a promising avenue for developing new anti-inflammatory and anti-pneumonia agents.

Purpose of the Study:

• To investigate the therapeutic potential of kurarinone, a prenylated flavanone from Sophora flavescens Aiton, against LPS-induced pneumonia.
• To elucidate the underlying molecular mechanisms by which kurarinone exerts its anti-pneumonia effects.

Main Methods:

• Establishment of LPS-induced pneumonia models in C57BL/6 mice and BEAS-2B cells.
• Administration of kurarinone and dexamethasone (DEX) to mice prior to LPS inhalation.
• In vitro treatment of BEAS-2B cells with varying concentrations of kurarinone before LPS stimulation.
• Assessment of lung injury, inflammatory cell infiltration, MPO activity, and cytokine levels (IL-1β, TNF-α, IL-6).
• Evaluation of the impact of kurarinone on MAPK and NF-κB signaling pathways.

Main Results:

• Kurarinone significantly ameliorated lung injury and reduced inflammatory cell infiltration in LPS-induced pneumonia models.
• Treatment with kurarinone led to a marked decrease in MPO activity and pro-inflammatory cytokines (IL-1β, TNF-α, IL-6) in lung tissues.
• Kurarinone demonstrated a dose-dependent reduction in inflammatory markers (IL-1β, TNF-α, IL-6, iNOS, COX2) in LPS-treated BEAS-2B cells.
• Mechanistically, kurarinone inhibited the activation of MAPK and NF-κB pathways in both in vivo and in vitro models.

Conclusions:

• Kurarinone effectively alleviates LPS-induced pneumonia by suppressing inflammation through the inhibition of MAPK and NF-κB pathways.
• These findings highlight kurarinone as a potential therapeutic candidate for the treatment of pneumonia.
• This study provides a foundation for further research into natural flavonoids as novel anti-pneumonia agents.